Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists launch major effort to unravel mysterious brain inflammation disorders

NCT ID NCT01623076

First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 22 times

Summary

This study follows 150 people with rare neuroimmune disorders like neuromyelitis optica and transverse myelitis. Researchers collect medical data and blood samples over time to understand what causes inflammation and why some patients respond to treatments while others do not. The goal is to improve diagnosis and guide future therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could help doctors better understand and diagnose rare neuroimmune disorders, and may point toward more personalized treatments.

What could go wrong

This is an observational study, not a treatment trial. It will not directly test any new drug or therapy, so it may not lead to immediate changes in care.

Conditions

The condition(s) this trial relates to.

acute transverse myelitis neuromyelitis optica optic neuritis transverse myelitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.